ES2159549T3 - Derivados de 3-pirazolcarboxamida con una afinidad para el receptor de los cannabinoides. - Google Patents

Derivados de 3-pirazolcarboxamida con una afinidad para el receptor de los cannabinoides.

Info

Publication number
ES2159549T3
ES2159549T3 ES94402890T ES94402890T ES2159549T3 ES 2159549 T3 ES2159549 T3 ES 2159549T3 ES 94402890 T ES94402890 T ES 94402890T ES 94402890 T ES94402890 T ES 94402890T ES 2159549 T3 ES2159549 T3 ES 2159549T3
Authority
ES
Spain
Prior art keywords
alkilo
hydrogen
radical
nr5r6
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94402890T
Other languages
English (en)
Inventor
Francis Barth
Pierre Casellas
Christian Congy
Serge Martinez
Murielle Rinaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2159549T3 publication Critical patent/ES2159549T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS DEL 3PIRAZOLOCARBOXAMIDA DE FORMULA (I): EN LA QUE - G2,G3,G4,G5,G6 Y W2,W3,W4,W5,W6 SON IDENTICOS O DIFERENTES Y REPRESENTAN INDEPENDIENTEMENTE HIDROGENO, UN ATOMO DE CLORO, BROM O YODO, UN (C1-C3)ALKILO, UN (C1-C3)ALCOXI, UN TRIFLUORMETILO, UN GRUPO NITRO Y G4 REPRESENTA EVENTUALMENTE UN GRUPO FENILO; - R4 REPESENTA HIDROGENO O UN (C1-C6)ALKILO, - R1 REPRESENTA UN (C1C6)ALKILO O UN HIDROGENO; - R2 REPRESENTA -+NR3R5R6 O -NR5R6; R5 REPRESENTA HIDROGENO O UN (C1-C6)ALKILO Y R6 REPRESENTA HIDROGENO, UN (C1-C6)ALKILO, UN FENILO, UN (C3-C8)CICLOAKILO O R5 Y R6 JUNTOS CON EL ATOMO DE NITROGENO AL QUE ESTA UNIDOS CONSITUYEN UN RADICAL HETEROCICLICO, SATURADO O INSATURADO, DE 5 A 10 ESLABONES, NO SUSTITUIDO O SUSTITUIDO UNA O VARIAS VECES POR UN ALKILO EN C1-C6, UN BENCILO, UN FENILO, UN HIDROXILO, UN ALCOXI EN C1-C6, UN HALOGENO; - R3 REPRESENTA UN (C1-C6)ALKILO O R3 FORMA UN PUENTE CON UNO DE LOS ATOMOS DEL RADICAL HETEROCICLICO FORMADO POR NR5R6; SIEMPRE QUE CUANDO R2 REPESENTA NR5R6 Y R6 JUNTOS CON EL ATOMO DE NITROGENO AL QUE ESAN UNIDO CONSTITUYEN UN RADICAL HETEROCICLICO DISTINTO DE UN RADICAL SATIRADO DE 5 A 8 ESLABONES NO SUSTITUIDO O SUS SALES Y SUS SOLVATOS. LA PRESENTE INVENCION SE REFIERE A UN PROCESO DE OBTENCION DE ESTOS NUEVOS DERIVADOS, Y LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES94402890T 1993-12-17 1994-12-15 Derivados de 3-pirazolcarboxamida con una afinidad para el receptor de los cannabinoides. Expired - Lifetime ES2159549T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9315221A FR2714057B1 (fr) 1993-12-17 1993-12-17 Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
ES2159549T3 true ES2159549T3 (es) 2001-10-16

Family

ID=9454059

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94402890T Expired - Lifetime ES2159549T3 (es) 1993-12-17 1994-12-15 Derivados de 3-pirazolcarboxamida con una afinidad para el receptor de los cannabinoides.

Country Status (11)

Country Link
US (1) US5462960A (es)
EP (1) EP0658546B1 (es)
JP (1) JP3825062B2 (es)
AT (1) ATE201399T1 (es)
DE (1) DE69427269T2 (es)
DK (1) DK0658546T3 (es)
ES (1) ES2159549T3 (es)
FR (1) FR2714057B1 (es)
GR (1) GR3036378T3 (es)
PT (1) PT658546E (es)
SI (1) SI0658546T1 (es)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
DE19701277A1 (de) * 1997-01-16 1998-07-23 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
US6100259A (en) * 1997-01-21 2000-08-08 Smithkline Beecham Corporation Cannabinoid receptor modulators
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
ES2325304T3 (es) * 1999-04-28 2009-09-01 Toray Industries, Inc. Materiales para eliminar canabinoides y columnas para la eliminacion de canabinoides con el uso de los mismos.
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
AU780572B2 (en) * 1999-10-18 2005-04-07 University Of Connecticut, The Pyrazole derivatives as cannabinoid receptor antagonists
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
CA2435409A1 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1414775B1 (en) * 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
JP2005509032A (ja) * 2001-11-14 2005-04-07 シェーリング　コーポレイション カンナビノイドレセプターリガンド
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
CA2478338A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1539693B9 (en) 2002-06-19 2008-10-08 Schering Corporation Cannabinoid receptor agonists
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
MXPA05000962A (es) 2002-07-29 2005-05-16 Hoffmann La Roche Nuevos benzodioxoles.
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
EP1546115A4 (en) * 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituted pyrimidines
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CN100349862C (zh) 2002-11-25 2007-11-21 先灵公司 大麻素受体配体
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7135488B2 (en) 2003-01-02 2006-11-14 Hoffmann-La Roche Inc. Pyrrolyl-thiazole derivatives
MXPA05007114A (es) 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
PL378841A1 (pl) * 2003-04-21 2006-05-29 Daiichi Pharmaceutical Co., Ltd. Pochodna pięcioczłonowego układu heterocyklicznego
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
EP1622876A1 (en) * 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
CA2528785A1 (en) 2003-06-20 2005-01-06 Matthias Heinrich Nettekoven 2-amidobenzothiazoles as cb1 receptor inverse agonists
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
CN100509808C (zh) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
CN100572375C (zh) 2004-01-28 2009-12-23 霍夫曼-拉罗奇有限公司 螺－苯并间二氧杂环戊烯及其作为cb1拮抗剂的应用
BRPI0507786A (pt) * 2004-02-20 2007-07-17 Astrazeneca Ab composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
ES2324720T3 (es) 2004-05-10 2009-08-13 F. Hoffmann-La Roche Ag Pirrol o imidazol amidas para tratar la obesidad.
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US7750158B2 (en) * 2004-06-22 2010-07-06 Schering Corporation Cannabinoid receptor ligands
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2873372B1 (fr) * 2004-07-22 2006-09-08 Sanofi Synthelabo Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
AU2005298986A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
BRPI0517653A (pt) 2004-11-09 2008-10-14 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
JP2008525404A (ja) * 2004-12-23 2008-07-17 アストラゼネカ アクチボラグ 治療剤
CA2594488C (en) 2005-01-10 2015-04-28 University Of Connecticut Novel heteropyrrole analogs acting on cannabinoid receptors
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
KR100970055B1 (ko) * 2005-06-22 2010-07-16 에프. 호프만-라 로슈 아게 6-(플루오로-벤조[1,3]디옥솔일)-모폴린-4-일-메탄온 및ｃｂ1 리간드로서 그의 용도
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
WO2007016771A1 (en) * 2005-08-05 2007-02-15 Uti Limited Partnership Dosing regimen for weight loss
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP1915131A4 (en) * 2005-08-12 2012-07-25 Astrazeneca Ab PROCESS
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007026215A1 (en) * 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
CN100999517B (zh) * 2006-01-11 2010-12-15 北京摩力克科技有限公司 吡唑甲酰胺衍生物,药物组合物和其制备方法
CN101437398A (zh) 2006-03-10 2009-05-20 詹里恩探索公司 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
EP2061783A2 (en) * 2006-09-11 2009-05-27 Hetero Drugs Limited Improved process for rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008039023A1 (en) 2006-09-29 2008-04-03 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
US8431609B2 (en) 2007-02-19 2013-04-30 Darmesh Mahendrabhai Shah Process for preparation of pyrazole derivatives
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
FR2919868A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
FR2919861A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US8133904B2 (en) 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102260246B (zh) * 2010-05-28 2014-08-13 范如霖 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN110372627B (zh) * 2019-07-04 2022-12-06 南昌大学 一种1,3,4-噁二唑衍生物及其制备方法和应用
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
CN115636788B (zh) * 2022-10-31 2025-03-04 合肥工业大学 一种利莫那班n-甲基类似物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.

Also Published As

Publication number Publication date
DK0658546T3 (da) 2001-09-10
DE69427269D1 (de) 2001-06-28
ATE201399T1 (de) 2001-06-15
JPH07324076A (ja) 1995-12-12
EP0658546B1 (fr) 2001-05-23
FR2714057B1 (fr) 1996-03-08
FR2714057A1 (fr) 1995-06-23
GR3036378T3 (en) 2001-11-30
DE69427269T2 (de) 2002-03-14
SI0658546T1 (en) 2001-10-31
JP3825062B2 (ja) 2006-09-20
US5462960A (en) 1995-10-31
PT658546E (pt) 2001-11-30
EP0658546A1 (fr) 1995-06-21

Similar Documents

Publication Publication Date Title
ATE201399T1 (de) 3-pyrazelcarboxamidderivate mit cannabinoid- rezeptor-affinität
ES2164758T3 (es) Derivados de morfolina sustituidos y su uso como agentes terapeuticos.
ES2075121T3 (es) Nuevos compuestos triciclicos.
PE20040479A1 (es) Inhibidores de proteasa del vih y composiciones que los contienen
PA8442101A1 (es) Pirazoles parasiticidas
ES2178038T3 (es) Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
CR7069A (es) Derivados de pirazol para el tratamiento de vih
ES2127919T3 (es) 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos.
ES2162857T3 (es) Derivados fenilicos trisustituidos utilizados como inhibidores de fosfodiesterasa.
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
PA8450401A1 (es) Pirazolopirimidonas para la disfuncion sexual
PA8463001A1 (es) Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p
ES2185665T3 (es) Derivados de benzofurano como antagonistas de taquicininas.
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
NO302819B1 (no) Nye pyrazolderivater og farmasöytiske blandinger som inneholder dem
ES2196554T3 (es) Derivados del 1,4-diazacicloheptano y su empleo en tintes para el cabello por oxidacion.
ES2100314T3 (es) Derivados de la pirimidina, su procedimiento de preparacion, productos intermedios obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que las contienen.
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR012924A1 (es) Derivados de tiazolidindiona, oxazolidindiona y oxadiazolidindiona, proceso para su preparacion, composiciones y formulaciones farmaceuticas, usode dichos compuestos para la fabricacion de formulaciones y metodo de tratamiento
ATE243209T1 (de) Tetrahydro gamma-carboline
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2045126T3 (es) Agentes terapeuticos.
ES2133177T3 (es) Iminooximetilenanilidas, procedimiento para su obtencion y agentes pesticidas que les contienen.
ES2031509T3 (es) Un procedimiento para la preparacion de agentes antiarritmicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658546

Country of ref document: ES